http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109200270-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate | 2018-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109200270-B |
| titleOfInvention | A combination drug that can improve the therapeutic effect of polypeptide vaccine on HPV-infected tumors and its application |
| abstract | The invention discloses a combined medicine and its application which can improve the therapeutic effect of a polypeptide vaccine on benign and malignant tumors caused by human papilloma virus (HPV) infection. The combined medicine comprises at least (i) a polypeptide vaccine with specific immune function and (ii) a polypeptide composition comprising F1 and F3. The F1 and F3 polypeptide compositions can stimulate tumor cells to secrete the inflammatory factor MCP-1, and attract inflammatory cells such as T cells and NK cells into the tumor tissue. It can inhibit the growth of TC-1 tumor cells in mice. The F1 and F3 polypeptide compositions can improve the efficiency of the therapeutic vaccine in the present application, and can prolong the survival time of tumor-bearing mice immunized with the therapeutic vaccine. The combined use of the polypeptide vaccine of the combined medicine and the F1 and F3 polypeptide compositions according to the respective effective dose ratios has better effect than the separate use of the two effective doses, and has a synergistic effect. |
| priorityDate | 2018-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.